Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23822993 | 0.84 | SIGMAR1 (0.33) | L3MBTL3L3MBTL1MBTD1TP53SIGMAR1 | |
| SCHEMBL24485995 | 0.83 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1TP53OPRM1 | |
| SCHEMBL22456358 | 0.83 | TSHR (0.40) | L3MBTL1TP53SIGMAR1OPRM1OPRL1 | |
| SCHEMBL20094631 | 0.82 | SIGMAR1 (0.49) | TP53SIGMAR1MEN1TSHRKMT2A | |
| SCHEMBL22280407 | 0.81 | SMN1; SMN2 (0.36) | L3MBTL3L3MBTL1TP53OPRL1HRH3 | |
| SCHEMBL26023136 | 0.81 | HRH3 (0.35) | TP53SIGMAR1OPRM1OPRL1HRH3 | |
| SCHEMBL278657 | 0.79 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL8263855 | 0.79 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL8255448 | 0.79 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL24127742 | 0.79 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1TP53SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | LCK, WEE1, JAK1 | L3MBTL3 1566/4885L3MBTL1 682/4885MBTD1 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.